Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.


Pharmaceutical Technology


Using the inequality that, for two events A and B:

P(A and B) = P(A) + P(B) – P(A or B) ≥ P(A) + P(B) – 1

It follows that:

P(S 2) = P(C 21 and C 22) ≥ max {P(C 21) + P(C 22) – 1, 0}

Since criterion C 21 is similar to S 1 except for n = 30 and k = 2.0 in the former while n = 10 and k = 2.4 in the latter, the calculation of P(C 21) is carried out similarly as in P(S 1) with n = 30 and k = 2.0. Therefore:



Therefore, a lower bound on the probability of passing USP requirements is max {P(S 1), P(S 2)}.


Figure 1. 95% lower bound on passing the USP test for dose uniformity (target 5 100%).
For a given value of μ and a given value of σ, a lower bound (LBOUND) can be determined using the above calculations. Figure 1 shows a contour for the combinations of μ and σ that have an LBOUND of 95% assuming a target, T, of 100. Any combination of μ and σ at or below the contour results represents at least a 95% chance of samples passing the USP content uniformity test.

The "true" probability of passing the USP test can be found by simulation. Table I gives a comparison of the simulated probabilities and the LBOUND calculation.


Table I: Simulated (SIM) versus lower bound (LB) probabilities of passing content-uniformity test.
As can be seen in Table I, the LBOUND calculations are fairly close to the simulated results across various population means and standard deviations.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here